US 10,471,146 B2 · Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method

Abstract

An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Claims12

Dependent claims

An anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof comprising the following CDR sequences:

(SEQ ID NO:
72)
heavy chain CDR1:
DYWVS,
(SEQ ID NO:
73)
heavy chain CDR2:
EIYPNSGATNFNENFK,
(SEQ ID NO:
74)
heavy chain CDR3:
DGTMGIAYYFDY,
(SEQ ID NO:
75)
light chain CDR1:
KASQNINRYLN,
(SEQ ID NO:
76)
light chain CDR2:
NANSLQT,
and
(SEQ ID NO:
77)
light chain CDR3:
LQHNSWPYT.

22 more elements

Dependencies are inferred from the claim text.

Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method

Life of this patent

Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method

Life of this patent

Abstract

Claims12